DP
RNAC icon

Diadema Partners’s Cartesian Therapeutics RNAC Stock Holding History

Diadema Partners’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$907K Buy
+87,057
New +$645K 0.11% 106

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Diadema Partners's RNAC Position: Q2 2026 in Review

Diadema Partners opened a new position in Cartesian Therapeutics (RNAC) in Q2 2026: 87,057 shares worth $907K. The stake represents 0.11% of the portfolio and ranks #106 among its holdings.

95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Diadema Partners held 87,057 shares of Cartesian Therapeutics worth $907K as of Q2 2026.
  • Cartesian Therapeutics was a new Diadema Partners position in Q2 2026.
  • Cartesian Therapeutics made up 0.11% of Diadema Partners's portfolio in Q2 2026, its #106 holding.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.